8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 22, 2026·SEC
Material company update
May 14, 2026·SEC
Tempest Therapeutics, Inc.(TPST)Earnings, Financials & Key Ratios
TPST•NASDAQ
$1.07
Price updated Jul 6, 2026
AboutTempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.Show more
- Revenue$0
- EBITDA-$26M+36.8%
- Net Income-$26M+37.2%
- EPS (Diluted)-6.33-322.0%
- ROE-203.63%-11.7%
TPST Price & Volume
Tempest Therapeutics, Inc. (TPST) stock price & volume — 10-year historical chart
Loading chart...
TPST Growth Metrics
Tempest Therapeutics, Inc. (TPST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.8%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-38.31%
Return on Capital
10 Years-73.84%
5 Years-94.47%
3 Years-107.67%
Last Year-130%
TPST Recent Earnings
Tempest Therapeutics, Inc. (TPST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$2.53-803.6%
$0.28
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.62+0.0%
$0.62
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.79+75.8%
$3.27
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$2.07+35.9%
$3.23
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $2.53vs $0.28-803.6% | — |
| Q2 2026 | Mar 31, 2026 | $0.62vs $0.62+0.0% | — |
| Q4 2025 | Nov 5, 2025 | $0.79vs $3.27+75.8% | — |
| Q3 2025 | Aug 11, 2025 | $2.07vs $3.23+35.9% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Tempest Therapeutics, Inc. (TPST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.07 | $4.75M | -0.17 | — | — | -203.63% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — | |
| $37.39 | $2.22B | -5.25 | 48.03% | -639.84% | -34.11% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — |
Compare TPST vs Peers
Tempest Therapeutics, Inc. (TPST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TPST SEC Filings & Documents
Tempest Therapeutics, Inc. (TPST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TPST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TPST Frequently Asked Questions
Tempest Therapeutics, Inc. (TPST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is TPST profitable?
Tempest Therapeutics, Inc. (TPST) reported a net loss of $43.1M for fiscal year 2025.
Dividend & Returns
What is TPST's return on equity?
Tempest Therapeutics, Inc. (TPST) has a return on equity (ROE) of -203.6%. Negative ROE indicates the company is unprofitable.
What is Tempest Therapeutics, Inc.'s free cash flow?
Tempest Therapeutics, Inc. (TPST) had negative free cash flow of $26.4M in fiscal year 2025, likely due to heavy capital investments.